ArticleNeurology and therapy2025
Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray.
Article in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWhile the literature on esketamine use in commercially insured patients with treatment-resistant depression (TRD) is growing, data on Medicaid beneficiaries remain limited. This study aimed to fill this gap by exploring characteristics of Medicaid beneficiaries with TRD who initiated esketamine treatment in the United States.
methodsAdults with TRD initiating esketamine on/after 03/05/2019 (index date) were selected from the Merative™ MarketScan
resultsA total of 151 patients were identified (mean age: 40.6 years; female: 70.2%; racial minorities: 31.1%). The most common comorbidities were anxiety (81.5%), sleep-wake disorders (47.0%), trauma-related disorders (43.0%), substance-related disorders (30.5%), and obesity (30.5%). Patients completed a mean of 22.5 esketamine sessions; 67.5% of patients completed the induction phase (≥ 8 sessions), 62.3% initiated the maintenance phase, and 53.0% completed ≥ 12 sessions. After esketamine initiation, patients had a mean of 0.02 inpatient admissions, 0.09 inpatient days, 0.31 emergency department visits, and 5.85 outpatient visits monthly. The mean follow-up medical costs were $2075 monthly, including inpatient costs of $97, emergency department costs of $51, and outpatient costs of $1902.
conclusionMedicaid beneficiaries with TRD who initiated esketamine treatment had a high comorbidity burden and a higher proportion of racial minorities than the US population overall. Nonetheless, most patients progressed to maintenance phase of esketamine treatment. Findings suggest that esketamine may be a viable treatment option for this complex patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.